Small molecular compounds such as OSU-CG5 and monoclonal antibodies targeting CD90 have already been used to inhibit CD90+ tumor cells in solid or hematological malignancy (Ishiura et al., 2010; Chen et al., 2015). Here, THY1 is linked to neoplasm.